Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML.
Saved in:
| Title: | Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. |
|---|---|
| Authors: | Basheer F; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.; Department of Haematology, University of Cambridge, Cambridge, UK.; Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge, UK., Giotopoulos G; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.; Department of Haematology, University of Cambridge, Cambridge, UK.; Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge, UK., Meduri E; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.; Department of Haematology, University of Cambridge, Cambridge, UK.; Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge, UK., Yun H; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.; Department of Haematology, University of Cambridge, Cambridge, UK.; Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge, UK., Mazan M; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.; Wellcome Trust Sanger Institute, Hinxton, UK., Sasca D; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.; Department of Haematology, University of Cambridge, Cambridge, UK.; Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge, UK., Gallipoli P; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.; Department of Haematology, University of Cambridge, Cambridge, UK.; Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge, UK., Marando L; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.; Department of Haematology, University of Cambridge, Cambridge, UK.; Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge, UK., Gozdecka M; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.; Wellcome Trust Sanger Institute, Hinxton, UK., Asby R; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.; Department of Haematology, University of Cambridge, Cambridge, UK.; Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge, UK., Sheppard O; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.; Department of Haematology, University of Cambridge, Cambridge, UK.; Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge, UK., Dudek M; Wellcome Trust Sanger Institute, Hinxton, UK., Bullinger L; Charité University Hospital, Berlin, Germany., Döhner H; Department of Internal Medicine III, University of Ulm, Ulm, Germany., Dillon R; Department of Medical and Molecular Genetics, Kings College School of Medicine, UK., Freeman S; Department of Clinical Immunology, University of Birmingham Medical School, Edgbaston, Birmingham, UK., Ottmann O; Department of Haematology, University of Cardiff, Cardiff, UK., Burnett A; Isle of Arran, UK., Russell N; Department of Haematology, University of Nottingham, Nottingham, UK., Papaemmanuil E; Departments of Epidemiology and Biostatistics and Cancer Biology, the Center for Molecular Oncology and the Center for Hematologic Malignancies, Memorial Sloan-Kettering Cancer Center, New York, NY., Hills R; Nuffield Department of Population Health, University of Oxford, Oxford, UK., Campbell P; Wellcome Trust Sanger Institute, Hinxton, UK., Vassiliou GS; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.; Department of Haematology, University of Cambridge, Cambridge, UK.; Wellcome Trust Sanger Institute, Hinxton, UK., Huntly BJP; Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK bjph2@cam.ac.uk.; Department of Haematology, University of Cambridge, Cambridge, UK.; Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Cambridge, UK. |
| Source: | The Journal of experimental medicine [J Exp Med] 2019 Apr 01; Vol. 216 (4), pp. 966-981. Date of Electronic Publication: 2019 Mar 19. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Rockefeller University Press Country of Publication: United States NLM ID: 2985109R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1540-9538 (Electronic) Linking ISSN: 00221007 NLM ISO Abbreviation: J Exp Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
